4D Molecular Therapeutics (NASDAQ:FDMT) Research Coverage Started at Morgan Stanley

Morgan Stanley initiated coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note published on Thursday morning, MarketBeat Ratings reports. The firm issued an underweight rating and a $8.00 price objective on the stock.

Several other equities research analysts have also weighed in on the company. Chardan Capital restated a “buy” rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Leerink Partners reissued an “outperform” rating and set a $36.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, Royal Bank of Canada lowered their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.13.

4D Molecular Therapeutics Price Performance

FDMT stock opened at $7.79 on Thursday. The firm has a 50-day moving average of $9.56 and a 200 day moving average of $16.45. The company has a market cap of $360.12 million, a P/E ratio of -2.73 and a beta of 2.82. 4D Molecular Therapeutics has a 1 year low of $7.32 and a 1 year high of $36.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $40,000. Values First Advisors Inc. purchased a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth $57,000. Quest Partners LLC grew its position in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after acquiring an additional 5,745 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after purchasing an additional 3,922 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new position in 4D Molecular Therapeutics in the 3rd quarter worth $108,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.